CEO
Topadur Pharma
Topadur Pharma AG develops dual-acting drugs utilizing its proprietary DualTOP™ technology platform to enhance cGMP-Enzyme Regulation, thereby improving blood circulation and cell communication. The company targets aging diseases characterized by reduced blood flow and dysregulated cellular interactions, including chronic wounds and age-related macular degeneration.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$20.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Reto Naef
Chairman
Product
Problem
Aging and related diseases often involve reduced blood circulation and impaired cell-to-cell communication, stemming from imbalances in cGMP levels. This can lead to conditions like chronic wounds, skin fibrosis, age-related macular degeneration, and diabetic retinopathy.
Solution
Topadur Pharma AG develops dual-acting drugs that target the cGMP-Enzyme Regulation System using its proprietary DualTOP™ technology platform. These drugs regulate the activity of sGC and PDE5 enzymes to increase cGMP levels, which restores healthy blood flow and corrects insufficient cell-to-cell communication. This approach aims to address the underlying causes of aging diseases, offering potential treatments for conditions characterized by reduced blood flow and dysregulated cellular interactions. The company is focused on developing a portfolio of drug candidates to address unmet needs in aging diseases.
Target Audience
The primary target audience includes individuals suffering from aging-related diseases characterized by reduced blood flow and dysregulated cell communication, as well as healthcare providers seeking innovative treatments for these conditions.
Features
- DualTOP™ technology platform for developing dual-acting drugs.
- Compounds regulate sGC and PDE5 enzyme activity.
- Increases cGMP levels to improve blood circulation.
- Corrects insufficient cell-to-cell communication.
- Targets aging diseases with reduced blood flow.
- Addresses conditions like chronic wounds and macular degeneration.